(0.17%) 5 163.75 points
(0.15%) 38 890 points
(0.15%) 18 029 points
(1.09%) $78.96
(-0.19%) $2.14
(0.82%) $2 327.50
(2.41%) $27.33
(0.88%) $973.75
(-0.03%) $0.929
(-0.27%) $10.84
(-0.27%) $0.795
(-0.07%) $91.39
Live Chart Being Loaded With Signals
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States...
Stats | |
---|---|
本日の出来高 | 1.26M |
平均出来高 | 1.23M |
時価総額 | 4.97B |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 752.50 |
ATR14 | $0.0130 (0.09%) |
ボリューム 相関
Telix Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Telix Pharmaceuticals 相関 - 通貨/商品
Telix Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $496.66M |
総利益: | $308.50M (62.12 %) |
EPS: | $0.0163 |
FY | 2023 |
収益: | $496.66M |
総利益: | $308.50M (62.12 %) |
EPS: | $0.0163 |
FY | 2022 |
収益: | $160.10M |
総利益: | $29.34M (18.32 %) |
EPS: | $-0.340 |
FY | 2021 |
収益: | $4.90M |
総利益: | $2.35M (47.98 %) |
EPS: | $-0.313 |
Financial Reports:
No articles found.
Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。